A phase III trial of bevasiranib, a treatment for wet age-related macular degeneration and the most advanced RNAi drug candidate in human testing, has been halted early after being deemed "unlikely" to meet its primary endpoint, the therapy's developer said last week.

According to Opko Health, the trial's independent data-monitoring committee had recommended ending the study after reviewing preliminary data, which "showed activity of bevasiranib … [but] indicated that the trial, as structured, was unlikely to meet its primary endpoint."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.